Fig. 7From: Pan-cancer analysis identified IGF2BP2 as a potential prognostic biomarker for multiple tumor typesDrug sensitivity analysis of IGF2BP2. The expression of IGF2BP2 was associated with the sensitivity of Dexrazoxane (A), Etoposide (B), SR16157 (C), Teniposide (D), Raloxifene (E), M-AMSA (F), Fulvestrant (G), XK-469 (H), Ribavirin (I), Zalcitabine (J), Bendamustine (K), Idarubicin (L), Nitrogen mustard (M), Tamoxifen (N), IDOXURIDINE (O), and Mitoxantrone (P)Back to article page